our institutional pharmacists, performed a lay Internet search for news stories, and reviewed the following journals for the period of January 1, 2009 through April 1, 2010: New England Journal of Medicine, Annals of Internal Medicine, ACP Journal Club, JAMA, Journal Watch, The Medical Letter, Medical Letter Treatment Updates, and the Lancet. We have chosen to discuss one recently approved drug and one novel drug in the pipeline: dronedarone for the treatment of atrial fibrillation and roflumilast as a controller medication for chronic obstructive pulmonary disease.
For the second half of this update, we identified new guidelines and reviews that aim to optimize our use of existing drugs for the treatment of common conditions in primary care. We used the same search strategy as that for new drugs and have elected to discuss osteoporosis, aspirin, and vitamin D. This paper derives from a presentation at the 33rd annual meeting of the Society of General Internal Medicine in April 2010.
NEW DRUGS Dronedarone
Atrial fibrillation (AF) is the most common clinically significant arrhythmia. Its prevalence increases with age. For example, among individuals ≥80 years old, the prevalence is 9.0%. 2 The landmark AFFIRM study, published in 2002, demonstrated that among patients who are anticoagulated to prevent stroke, 5-year mortality rates do not differ between patients randomly assigned to rate control versus rhythm control (21.3% vs 23.8%, p=0.08). 3 Therefore, clinicians should use antiarrhythmic medication selectively, rather than routinely, for patients with atrial fibrillation. Indications include to: (1) alleviate symptoms in symptomatic patients, (2) prevent tachycardiainduced cardiomyopathy, (3) prevent hemodynamic compromise, and (4) improve exercise capacity. Amiodarone is commonly used for patients with an indication for antiarrhythmic therapy, particularly for those with an impaired ejection fraction. However, amiodarone has many serious potential side effects in long-term use, including pulmonary, thyroid, and hepatic toxicity. Dronedarone is a new antiarrhythmic drug that is structurally similar to amiodarone except that it contains no iodine. It was approved by the FDA in July 2009. Dronedarone is a class 3 antiarrhythmic agent that works primarily as a slow and rapid potassium channel blocker. Like amiodarone, it also is an alpha and beta adrenergic antagonist. By adding a methyl sulfonamide group, it has a reduced half life (13-19 h) with less tissue accumulation than amiodarone.
The first trials to evaluate the efficacy of dronedarone were the EURIDIS and ADONIS trials, which were identical randomized controlled trials (combined n=1,237) of patients with at least one recent episode of atrial fibrillation (<3 months) who were in sinus rhythm at the time of randomization. 4 Exclusion criteria included, among others, permanent AF, HR<50 (due to the beta-blocking properties of the drug), significant conduction disease, New York Heart Association (NYHA) class III or IV heart failure, chronic kidney disease, and baseline liver, pulmonary, or endocrine disease. Patients received dronedarone 400 mg twice daily or placebo for 1 year. The benefit of the drug was modest. At 12 months, most patients in each group had developed a recurrence of AF (67% vs 78%, respectively, p = 0.01). Median time to first recurrence increased from 41 to 96 days. Mortality and hospitalization rates did not differ between the two groups. There was no observed thyroid, pulmonary, hepatic, or neurologic toxicity. The next study was the ANDROMEDA trial of 627 patients who had been hospitalized with NYHA class III or IV heart failure. 5 Notably, these were among the patients who were excluded in the EURIDIS and ADONIS trials. Only 25% of patients were in AF at study entry. At 2 months, mortality was 8.1% in the dronedarone group and only 3.8% in the placebo group. Most of the excess mortality was due to heart failure. Rates of hospitalization for cardiac causes and new onset renal dysfunction were also higher in the dronedarone group. The results were unexpected and prompted the FDA to deny a June 2005 new drug application for dronedarone. In 2009, investigators published the results from ATHENA; the study population (n=4,628) was more diverse than in the earlier trials and included patients with paroxysmal or persistent AF and at least one major risk factor for stroke. However, patients with NYHA class IV heart failure were excluded. The primary outcome of first hospitalization for cardiac causes or death was significantly less common among patients receiving the drug than among those receiving placebo (31.9% vs 39.4%, p<0.001). Mortality did not differ between the groups (5.0% vs 6.0%, respectively, p=0.18); however cardiovascular mortality was lower among patients receiving the drug (2.7% vs 3.9%, respectively, p=0.03). This large trial provided some comfort regarding the safety of longer term use of dronedarone in selected patients. Finally, the DIONYSOS trial, which has not yet been subjected to peer review, showed that dronedarone was inferior to amiodarone in maintaining sinus rhythm for patients with a history of AF. 6 Rates of recurrent AF were 64% vs. 42%, respectively.
Dronedarone is less effective than amiodarone in maintaining sinus rhythm for patients with AF and increases mortality among patients with recently decompensated or NYHA class III or IV heart failure. The FDA advises against use in these settings in a black box warning. It is however generally well tolerated and does not have the principal iodine-related toxicities of amiodarone. It is contraindicated for patients with sinus bradycardia <50 or significant conduction system disease. Its cost (260 USD per month) is considerably more than that of amiodarone (100 USD per month). 7 What is the role of this new drug in clinical practice? It has a role for patients with a compelling indication for amiodarone who have a contraindication to it use or who have had important side effects with its use in the past. Despite its apparent safety, due to higher cost and lower efficacy, it should not be a first line antiarrhythmic medication to maintain AF.
Roflumilast
Cigarette smoking is the leading preventable cause of death in the US and most of the developed world. One consequence, chronic obstructive pulmonary disease (COPD), is a progressive, disabling disease that is the fourth leading cause of death in the US. 8 The GOLD classification is commonly used to stratify severity of disease in patients with COPD (Table 1) . Unfortunately, despite current optimal therapy, many patients with stage III or stage IV COPD have disabling symptoms that restrict activity and lifestyle. In addition, no existing treatment has been shown to slow the expected progression of COPD over time. While tiotropium reduces hospitalizations and the risk of exacerbation, it does not reduce the rate of decline in forced expiratory volume in 1 s (FEV1). 9 Finally, survival for patients with advanced COPD is poor; the 10-year survival rate for smokers >50 years old with stage III or IV COPD is only 15%. 10 Clearly, there is a need for more effective therapy. In this context, roflumilast is a novel anti-inflammatory agent that inhibits phosphodiesterase-4 (PDE4). PDE4 causes cytokine release, and recruitment and proliferation of macrophages, neutrophils, and lymphocytes. Roflumilast is an oral PDE4 inhibitor that can be given as a single daily dose. It has the potential to decrease airway inflammation and sputum production, 11 and to improve lung function in patients with COPD.
The first large trial to study the impact of roflumilast on clinical outcomes for patients with COPD was a randomized controlled trial (n =1,157) of two different doses of roflumilast versus placebo for 24 weeks. 12 Eligible patients were >40 years old who had a >10 pack-year cigarette history and GOLD stage II-III COPD. Exclusion criteria included asthma, an exacerbation of disease in the previous 4 weeks, and frequent (>8 puffs/day) use of a rescue inhaler. At 24 weeks, there was an improvement in post-bronchodilator FEV1 in both treatment groups as compared to a decline for placebotreated patients. The differences compared to placebo were 74 cc for roflumilast 250 mcg daily and 97 cc for roflumilast 500 mcg daily. Health-related quality of life, as determined by SGRQ (St. George's respiratory questionnaire) 13 symptom scores, were significantly improved for both doses of the drug when compared to placebo. In a secondary analysis, the mean number of exacerbations decreased with both doses of roflumilast when compared to placebo (0.75 vs 1.03 vs 1.13, respectively, p=0.01). Diarrhea and nausea were the most common drug-related adverse effects, occurring in 7% and 4% of patients, respectively. Subsequently, Calverley and colleagues reported the results of a study that restricted eligibility to patients (n= 1,514) with severe COPD (FEV1<50%) who used the higher dose of roflumilast (500 mcg daily) and followed the patients for 1 year.
14 Post-bronchodilator FEV1 declined during treatment, but to a lesser degree than for placebo treated patients (-35 cc vs -88 cc, p<0.01). Symptom scores and rates of exacerbations did not differ between the two group although exacerbations were fewer among the subset of patients with GOLD class IV COPD (1.01 vs 1.59, p=0.024). Roflumilast has also shown promise for the treatment of asthma. In a phase 2/3 trial that did not include a placebo arm, roflumilast conferred reduction in symptoms and rescue inhaler use. 16 The magnitude of improvement in FEV1 was greater than that seen when used for the treatment of COPD (400 cc for roflumilast 500 mcg daily for 12 weeks). Clinicians should, however, consider these results to be preliminary. Roflumilast has now been studied in nearly 7000 patients and has a favorable side effect profile. To date, no significant drug interactions have been reported. It is easy to administer as a single daily oral dose. Patients will become less symptomatic, with the possible exception of roflumilast taken together with salmeterol. It is unknown if patients with mild COPD, who were not included in the studies, would gain similar benefit. Importantly, it is the first drug shown to slow or reverse the expected fall in FEV1 over time. While existing studies do not extend beyond 1 year of treatment, it is possible that roflumilast may have a beneficial effect on long-term mortality; future studies and clinical experience may shed light on this question. In September 2009, the manufacturer filed a new drug application (NDA) for roflumilast with the FDA for the indication of symptomatic COPD. If approved, roflumilast has the potential to be a major advance in the treatment of moderate to severe COPD.
NEW GUIDELINES Osteoporosis
Three challenging issues in the management of patients with osteoporosis are the optimal frequency for bone mineral density (BMD) measurement, the relationship between bisphosphonate use and atypical femur fractures, and the duration of treatment with bisphosphonates.
The National Osteoporosis Foundation recommends that patients undergoing treatment for osteoporosis undergo BMD testing every 2 years. 17 In contrast, the North American Menopause Society 2010 guideline recommends checking BMD once, after 2 years of treatment. According to this guideline, if the BMD is stable or improved at 2 years, there is little value in repeating it. Their rationale includes the limited value of BMD testing in predicting effectiveness of treatment and recognition that changes in BMD lag behind therapeutic benefits of bisphosphonates. 18 In 2009, several small case series described patients on bisphosphonates for 5 or more years who developed atypical femur fractures. 19, 20 Hip fractures usually occur below the head of the femur, through the neck of the femur, and between the greater and lesser trochanter. In contrast, these atypical fractures were subtrochanteric, and diaphyseal, through the femur shaft. Subsequently, several larger scale studies have concluded that these atypical fractures are due to osteoporosis itself and not bisphosphonate use. For example, Danish investigators reported results of a cohort study of patients with prior non-hip fractures. 21 They compared 5,187 patients on alendronate to 10,374 patients who were matched by sex, age, and location of baseline fracture. They found no increase in atypical fractures among patients who were taking alendronate. Black and colleagues reviewed the hip fracture data from three large randomized bisphosphonate trials: the FIT trial in which patients took alendronate for up to 4.5 years, the FLEX trial, where patients took alendronate for up to 10 years, and the HORIZON-PFT trial where patients took zoledronic acid for up to 3 years. 22 A total of 283 fractures occurred among 14, 195 women; only 12 of these fractures occurred in the subtrochanteric or diaphyseal femur (2.3 per 10,000 patient-years). The relative hazard of treatment compared with placebo was not statistically significant, though the confidence intervals were wide ( Table 2 ). The authors concluded that subtrochanteric or diaphyseal fractures were rare even in women treated with bisphosphonates for up to 10 years. The accompanying editorial concluded that many more hip fractures are prevented by bisphosphonates than are potentially caused by them. 23 Schwartz and colleagues addressed the question of the optimal duration of alendronate therapy. 24 Their analysis of data from the FLEX trial concluded that continuing alendronate for 10 years instead of 5 years reduced non-vertebral fracture risk only for women whose femoral neck T scores, after completing 5 years of treatment, were -2.5 or less (RR=0.50, 95% CI 0.26-0.96). The implication for practice is that it is beneficial to continue bisphosphonates for 10 years only in 
Aspirin for Primary Prevention of Cardiovascular Disease
Recommendations for aspirin use for primary prevention of cardiovascular disease have evolved since the 2008 American Heart Association recommendations. The guidelines recommended aspirin for men with a 10-year risk of coronary heart disease of≥10% for primary prevention of myocardial infarction (MI), and for women if the benefit of ischemic stroke prevention outweighed the risk of the aspirin. 25 In 2009, the US Preventive Services Task Force published a new guideline that recommended aspirin for men aged 45-79 to decrease the risk of MI when the benefit outweighs the potential harm of increase in gastrointestinal (GI) hemorrhage (an "A" recommendation). A new contribution is the calculation of the Framingham 10-year cardiac risk level at which cardiovascular (CV) benefit exceeds GI harms (Table 3) . They recommend that women aged 55-79 should take aspirin when the reduction in ischemic stroke risk outweighs the potential harm of increase in GI hemorrhage (an "A" recommendation) ( Table 3) . They used the Framingham Stroke Risk calculator, [available online at: www.stroke-education.com/calc/risk_calc.do] 26 to calculate the 10-year risk of stroke. Factors that increase the risk of GI bleeding include: increasing age, male sex, taking NSAIDs plus aspirin, and history of GI ulcer. Enteric or buffered aspirin does not reduce risk. The optimum aspirin dose is unknown; 81 mg/day is as effective as higher doses, and GI bleeding risk may increase with higher aspirin doses. They found insufficient evidence to recommend aspirin for people ≥80 years old (an "I" statement), and did not recommend its use for men younger than 45 years and women younger than 55 years (a "D" recommendation). The Antithrombotic Trialists' Collaboration meta-analysis, published later in 2009, cast doubt on the value of aspirin for primary prevention. This study was a meta-analysis of serious vascular events and major bleeding in 6 primary and 16 secondary prevention trials of aspirin vs. control. 27 Aspirin for primary prevention was associated with a 12% reduction in serious vascular events due to a reduction in MI. There was no demonstrable effect on stroke or vascular mortality. There was a small but significant increase in bleeding rates: 0.1% vs. 0.07% per year, RR 1.54 (95% CI 1.30-1.82 ). The authors concluded that aspirin was of uncertain net value for primary prevention and that it was necessary to weigh the anticipated reduction in occlusive events against the increase in major bleeding complications.
There has also been re-assessment of the role of aspirin for primary prevention of CV events in diabetics. A recent metaanalysis of RCTs from 1966-2008 evaluated six eligible trials with a total of 10,117 participants. 28 Vitamin D deficiency is the most common basis for secondary osteoporosis. Vitamin D supplementation reduces the risk of fracture. The Women's Health Initiative, a randomized controlled trial of 36,282 women ages 50-69 assigned to calcium 100 mg/day plus vitamin D 400 IU/day or placebo, evaluated bone mineral density (BMD) and hip fractures. 33 Hip BMD was 1.06% higher in the calcium-vitamin D group. Compliant patients (defined as those who took more than 80% of medicine) had a significant decrease in hip fracture (HR 0.71, 95% CI 0.52-0.970). A meta-analysis of seven RCTs in 9,820 elderly subjects (mean age 79) showed that those receiving higher doses of vitamin D supplementation (700-800 IU/day) had lower rates of hip (RR 0.74, 95% CI 0.61-0.88) and vertebral (RR 0.77, 95% CI 0.68-0.87) fracture. 34 Several studies have found that vitamin D supplementation decreases the risk of falls. In a meta-analysis of 5 RCTs of vitamin D involving 1,237 older subjects (mean age 60), vitamin D use reduced the risk of falls by 22% compared with patients receiving calcium or placebo (OR 0.78, 95% CI 0.64-0.92). 35 The number needed to treat (NNT) to prevent one fall was 15 patients. In a subsequent report, 96 elderly women with poststroke hemiplegia were randomly assigned to treatment There is conflicting evidence about the relationship between vitamin D and cancer risk. Several observational studies have reported that high vitamin D levels are associated with decreased cancer risk. However, RCTs of vitamin D supplementation have shown no reduction in the risk of cancer. For example, in the Women's Health Initiative RCT, 36,282 women were randomly assigned to 1,000 mg calcium and 400 IU vitamin D3 or placebo for an average of 7 years. 33 At the completion of the trial, there was no difference in the incidence of colorectal cancer 38 or invasive breast cancer.
Observational studies have demonstrated associations between low vitamin D levels and increased all-cause and cardiovascular mortality. 39 A recent meta-analysis of randomized controlled trials reported lower all-cause mortality rates among patients receiving vitamin D supplementation (RR 0.92, 95% CI 0.86-0.99). 40 However, mortality was not a primary endpoint in any of these trials; a statistically significant benefit was not observed in any of the individual studies. Still, the random allocation of patients in these studies diminishes concerns about residual confounding. Future research should include large-scale population-based RCTs that evaluate mortality as the primary endpoint. Prevention of vitamin D deficiency is part of optimal primary care practice. As testing for vitamin D deficiency can be expensive, a reasonable approach is to provide adequate supplementation with 1,000 IU of vitamin D3 daily for all patients.
